

Luke Hughes-Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3687933/publications.pdf>

Version: 2024-02-01

12
papers

539
citations

1307594

7
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1199
citing authors

#	ARTICLE	IF	CITATIONS
1	Six versus 12 monthsâ€™™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	11
2	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , 2019, 393, 2599-2612.	13.7	225
3	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 506-506.	1.6	59
4	Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. <i>Modern Pathology</i> , 2017, 30, 1069-1077.	5.5	15
5	Aiming for a holistic integrated service for men diagnosed with prostate cancer â€™ Definitions of standards and skill sets for nurses and allied healthcare professionals. <i>European Journal of Oncology Nursing</i> , 2017, 29, 31-38.	2.1	4
6	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.3	31
7	PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS591-TPS591.	1.6	7
8	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470.	6.4	23
9	Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1014-1014.	1.6	3
10	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
11	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2A–2 factorial randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 201-212.	10.7	106
12	Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1015-1015.	1.6	2